- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
EmsanaRx Is Changing Its Name to AffirmedRx
EmsanaRx, the upstart pharmacy benefit manager (PBM) that says its priority is public health, announced yesterday that it is changing its name to AffirmedRx.
EmsanaRx was launched in late 2021 as project of Emsana Health, an independent company established by The Purchaser Business Group on Health, a coalition of large employers. Emsana Health bills itself as an “innovation studio” for healthcare.
According to a press release Emsana Health sold its equity stake back EmsanaRx.
The press release says that AffirmedRx will continue EmsanaRx’s work “to create a completely unconflicted pharmacy benefit manager that all large self-funded employers can be proud to collaborate with.”
Greg Baker, CEO of EmsanaRx, is staying CEO of AffirmedRx, which has adopted “patients over profits” as it tagline. Like EmsanaRx, AffirmedRex is a public benefit corporation, a legal status that allows the company to prioritize public good and not just shareholders.
Baker says in the new name reflects “our commitment to forging new paths with members to deliver innovation and flexibility.”
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen
Drug Discount Programs Poised to Change with New Tech, Pharma Execs Survey Finds
April 22nd 2024It is somewhat mind-boggling in 2024 that more than one-third of pharma organizations still rely on manual entry of data into Excel spreadsheets to track duplicate discounts that can cost millions of dollars a year in lost revenue
Read More
